Bacillus subtilis C-3102 Agent for Ruminant Mastitis Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preventing and treating mastitis in cows are inadequate, leading to significant economic losses and recurrence of the disease, with existing treatments often failing to completely cure subclinical mastitis and lacking effective preventive measures.
Innovation Solution
A preventive or therapeutic agent comprising Bacillus genus bacteria, specifically Bacillus subtilis strain C-3102, which increases or maintains CD11c+ CD172a+ blood dendritic cell gate 2, exhibits high Bifidobacterium-growing activity, and possesses protease and amylase activities, effectively preventing and treating mastitis when orally administered to cows.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotic therapy is administered to treat mastitis, then the infection is suppressed, but complete cure is rarely achieved and recurrence occurs
Solution Approach 1:
The patent applies preliminary action by administering viable bacterial agents (Bacillus subtilis, butyric acid bacteria, lactic acid bacteria) to cows before mastitis onset to establish protective microbiota in the mammary gland. This preventive colonization creates immune stimulation and competitive exclusion of pathogenic bacteria, preventing infection before it occurs and eliminating the need for curative antibiotics that fail to provide complete relief.
Solution Approach 2:
The patent uses viable bacterial agents as intermediaries between the host immune system and pathogenic bacteria. These beneficial bacteria act as mediators by stimulating the cow's immune response, producing antimicrobial substances, and creating a protective microbial environment that indirectly prevents mastitis without directly confronting the pathogenic bacteria like antibiotics do.
2Reliability
If antibiotics are administered to cure mastitis, then bacterial infection is reduced, but milk cannot be shipped during treatment causing economic loss
Solution Approach 1:
The patent implements preliminary action by establishing protective microbiota through oral administration of viable bacteria before mastitis develops. This preventive approach maintains milk quality and shipment capability while providing immune protection, eliminating the need to withhold milk during treatment periods associated with antibiotic therapy.
Solution Approach 2:
The patent employs readily available, safe viable bacterial agents that can be administered orally without regulatory restrictions affecting milk shipment. These microorganisms act as temporary protective agents that colonize the mammary tract, provide immune stimulation, and are naturally shed, allowing continuous milk production and shipment without the long withdrawal periods required for antibiotics.
3Reliability
If viable bacterial agents are used for prevention, then occurrence of mastitis decreases, but the specific effective strain was not identified in prior studies
Solution Approach 1:
The patent applies segmentation by evaluating and identifying specific strains within broader bacterial genera (Bacillus subtilis, butyric acid bacteria, lactic acid bacteria). Rather than using undefined viable agents, the patent isolates and characterizes particular strains with proven efficacy, segmenting the general category of probiotics into specific, identifiable, and replicable strain levels for consistent prevention results.
Solution Approach 2:
The patent employs feedback mechanisms by monitoring mastitis occurrence rates in cows administered specific bacterial strains and using this data to identify and select the most effective strains. The patent establishes criteria for evaluating prevention effectiveness and uses this feedback to refine strain selection, ensuring that only proven effective strains are recommended for mastitis prevention.
Data Source
AI summary
The present invention relates to a substance or method for preventing or treating mastitis in ruminant animals, particularly in dairy cows. Specifically provided are: a preventive or therapeutic agent, a feed additive, a feed, and a pharmaceutical composition for ruminant animal mastitis, characterized by comprising, as an active ingredient, a Bacillus genus bacterium having the property of being capable of increasing or maintaining CD11c+ CD172a+ blood dendritic cell gate 2 in cows.